Rakovina Therapeutics Inc (TSXV:RKV) is a preclinical oncology company with no approved products and no reported revenue, so its funding position matters as much as its science. In its second-quarter 2026 report, the company said it held cash of C$200,115 at 30 June 2026 against a Working Capital Deficit of C$2,129,848. In August 2026 it followed with a non-brokered private Placement totalling C$3,385,000 across two tranches. That is the practical answer to the headline: the raise is intended to keep its AI-assisted drug discovery work running.
What the company does
Rakovina develops cancer therapies aimed at DNA damage response, the set of cellular repair pathways that tumours often rely on to survive treatment. The company says it uses artificial intelligence to design and screen candidate molecules. It lists on the TSX Venture Exchange under RKV and, according to its own release, also on the Frankfurt Exchange.
Two preclinical candidates were presented at the American Association for Cancer Research (AACR) meeting in April 2026. The kt-5000 series is described as a dual ATR-mTOR inhibitor showing anti-tumour activity and the ability to reach the central nervous system. kt-3283 is described as a dual PARP/HDAC inhibitor, for which the company reports successful development of a lipid nanoparticle formulation. These are laboratory-stage results, and none of them has yet been tested in humans.
What the second-quarter numbers show
All figures below are in Canadian dollars for the three months ended 30 June 2026. The net loss was C$1,727,748, compared with C$2,916,944 in the second quarter of 2025, an improvement of 41% that reflects lower spending rather than any income. Research and Development expense was C$1,130,259 for the quarter and C$2,161,815 for the first half, against C$1,611,985 in the second quarter of 2025. General and administrative expense was C$450,695, which the company says is a 63% reduction on a year earlier.
Management also states that 72% of its budget was directed to AI-powered drug discovery. Taken together, the figures suggest a deliberate narrowing of the cost base towards the programmes the company regards as its core.
Why the financing matters
Cash of about C$200,000 is small against quarterly expenses of roughly C$1.6 million, and the working capital deficit indicates that current obligations exceeded current Assets at the period end. The C$3,385,000 placement, announced after the quarter closed, therefore changes the picture materially. On the reported run-rate it would cover a few quarters of operating spending, though the exact effect depends on how much of the money is received and how quickly costs are paid down.
The structure is also worth noting. A non-brokered placement of Equity issues new shares, which dilutes existing holders. The company has said it also intends to pursue non-dilutive funding, such as grants or partnerships, to reduce that reliance over time. Whether it succeeds is an open question.
Risks to weigh
Preclinical oncology is a long and uncertain path. Candidates that look promising in cell and animal models frequently Fail on safety or efficacy once they reach clinical trials, and each stage requires further capital. Rakovina has no product revenue, so continued access to equity markets is central to its survival.
The AI-driven approach is a further variable. Computational design can speed the identification of candidates, but it does not remove the need for conventional preclinical and clinical validation.
What to watch next
The company has said it intends to advance three AI-powered programmes and to seek non-dilutive funding. Readers should look for the third-quarter 2026 financial statements, which will show how much of the placement was received and how the cash position has moved. Further data on kt-5000 and kt-3283, any move towards regulatory filings, and any Partnership announcements would be the clearest indicators of progress.



![Arch Biopartners Inc. Turns Heads as Phase II kidney-drug development Sparks New Trading Interest on the TSXV Composite — Small Cap Growth Stock [TSXV:ARCH]](/featured_image/gallery/medium/shutterstock_2606085317_11_18_2026_16_10_43_645635.jpg)
![Vimy Pharmaceuticals Corp. Momentum Jumps as its new-listing debut Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:VIMY]](/featured_image/gallery/medium/shutterstock_512538715_11_18_2026_16_11_17_989273.jpg)
![WELLSTAR Technologies Corp. Momentum Jumps as record public-company quarterly growth Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:WSTR]](/featured_image/gallery/medium/shutterstock_2439951387_11_18_2026_16_11_37_467341.jpg)
Please wait processing your request...